Last Updated: September 24, 2026

ZOFRAN ODT Drug Patent Profile

Name: ZOFRAN ODT Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Zofran Odt patents expire, and what generic alternatives are available?

Zofran Odt is a drug marketed by Sandoz and is included in one NDA.

The generic ingredient in ZOFRAN ODT is ondansetron. There is one drug master file entry for this compound. Thirty suppliers are listed for this compound. Additional details are available on the ondansetron profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zofran Odt

A generic version of ZOFRAN ODT was approved as ondansetron by CHARTWELL MOLECULES on December 26^th, 2006.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ZOFRAN ODT?
What are the global sales for ZOFRAN ODT?
What is Average Wholesale Price for ZOFRAN ODT?

Summary for ZOFRAN ODT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	163
Patent Applications:	6,822
Drug Prices:	Drug price information for ZOFRAN ODT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZOFRAN ODT
DailyMed Link:	ZOFRAN ODT at DailyMed

Drug patent expirations by year for ZOFRAN ODT

Recent Clinical Trials for ZOFRAN ODT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
General Biophysics LLC	PHASE1
National Institute on Aging (NIA)	PHASE1
Tanta University	Phase 3

See all ZOFRAN ODT clinical trials

US Patents and Regulatory Information for ZOFRAN ODT

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	ZOFRAN ODT	ondansetron	TABLET, ORALLY DISINTEGRATING;ORAL	020781-001	Jan 27, 1999		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sandoz	ZOFRAN ODT	ondansetron	TABLET, ORALLY DISINTEGRATING;ORAL	020781-002	Jan 27, 1999		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ZOFRAN ODT

See the table below for patents covering ZOFRAN ODT around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Austria	392276		⤷ Start Trial
Austria	A20485		⤷ Start Trial
Australia	3809785		⤷ Start Trial
Australia	5261486		⤷ Start Trial
Australia	579132		⤷ Start Trial
Australia	583343		⤷ Start Trial
Belgium	901576		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.